📈 Jumpstart Signal Watchlist — July 30, 2026

🏢 What they do: DiamondRock Hospitality Company (DRH) is a self-advised real estate investment trust (REIT) that owns a portfolio of approximately 35-36 premium hotels and resorts with about 9,600 rooms, concentrated in U.S. gateway markets and leisure destinations.
- 🎯 Current $12.91 is 2% below 3yr high $13.13 · ⏳ SMA200 $9.94 (current price $12.91 is above) · 💰 Market Cap $2.6B
- DRH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (10.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 144% (>20%); Low LT D/E 0.72 (<1.0); PEG ratio 0.12 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ DIAMONDROCK HOSPITALITY COMPANY REPORTS SECOND QUARTER 2026 RESULTS, RAISES FULL-YEAR GUIDANCE AND INCREASES QUARTERLY COMMON DIVIDEND — Yahoo Finance / PR Newswire.
🤖 DiamondRock reported Q2 2026 revenue of $318.3 million and net income of $0.44 per share, with both results improving year over year. The company also raised full-year guidance and increased its quarterly common dividend by 22%, which is favorable for the stock.
✅ DiamondRock Hospitality (DRH) Q2 FFO and Revenues Beat Estimates — Yahoo Finance / Zacks.
🤖 The company’s Q2 funds from operations of $0.44 per share beat the Zacks consensus estimate of $0.37, and revenue also slightly exceeded expectations. Earnings beats and repeated outperformance versus consensus are generally positive signals for DRH.
✅ DiamondRock Hospitality (NYSE:DRH) Reaches New 12-Month High on Analyst Upgrade — MarketBeat.
🤖 Citigroup raised its price target on DRH to $13.00, and the stock hit a new 52-week high after the upgrade. Higher price targets and a fresh high typically support a positive near-term market reaction.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: Pitney Bowes is a technology-driven shipping, mailing, and financial services company. It provides tools and services such as postage meters, mailing equipment, shipping software, presort mail services, and parcel/shipping management solutions for businesses of all sizes.
- 🎯 Current $18.14 is 2% below 3yr high $18.51 · ⏳ SMA200 $12.60 (current price $18.14 is above) · 💰 Market Cap $3.6B
- PBI shows decent technicals supported by positive sentiment.

💎 Quality (Q): 44/60
- 🏦 Low drawdown (11.9% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; SMA50 recent crossover; SMA50 recent crossover; EPS growth 112% (>20%).
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Pitney Bowes Announces Financial Results for Second Quarter 2026 and Issues CEO Letter — Business Wire.
🤖 Pitney Bowes reported second-quarter 2026 financial results, repurchased 4.5 million shares, and approved a $0.10 quarterly dividend. The release also points to a stronger capital-return profile and sets up the earnings call, while later coverage says the company raised full-year profit and free-cash-flow guidance.
✅ Pitney Bowes Q2 Earnings Beat Estimates, Revenues Decline Y/Y — Yahoo Finance.
🤖 The company beat Q2 adjusted EPS and revenue expectations, and management raised 2026 adjusted EBIT, EPS, and free cash flow guidance. Revenue still declined year over year, but the stronger profitability outlook and debt reduction were viewed favorably for the stock.
❌ Pitney Bowes CEO Kurt Wolf sells $8.87m in company shares — Investing.com.
🤖 Large insider selling by the CEO can weigh on investor sentiment because it may signal reduced confidence or simply create overhang in the stock. The article notes multiple sales in early July, which is likely a mild negative for $PBI.
🍭 Bonus (B): 0/10 — Office Machines

🏢 What they do: Sotera Health is a global healthcare services company that provides sterilization solutions, laboratory testing, and technical advisory services to help ensure medical and pharmaceutical products are safe for use.
- 🎯 Current $17.85 is 8% below 3yr high $19.35 · ⏳ SMA200 $16.46 (current price $17.85 is above) · 💰 Market Cap $5.1B
- SHC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 280% (>20%); ROE 19% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.16 (<1.5).
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive.
✅ Sotera Health Company (NASDAQ:SHC) Given Average Rating of "Moderate Buy" by Brokerages — MarketBeat.
🤖 The article says SHC has a consensus "Moderate Buy" rating, with 8 of 11 analysts recommending buy and an average 1-year price target of $20.25. It also references recent better-than-expected quarterly results, which is supportive for the stock.
⚪️ Sotera Health Announces Second-Quarter 2026 Earnings Release Date — Yahoo Finance / Globe Newswire.
🤖 This is a bare earnings-date announcement with no results, guidance, or analyst opinion. It is not materially informative for SHC’s stock price on its own, so it is neutral.
⚪️ Sotera Health Company $SHC Shares Bought by Irenic Capital Management LP — MarketBeat.
🤖 This is mostly an ownership and holdings update, not a fundamental business catalyst. It repeats prior earnings results and insider-sale context, but does not present a new company-specific development likely to move the stock materially.
🍭 Bonus (B): 0/10 — Misc Health & Allied Services

🏢 What they do: John Wiley & Sons, Inc. (Wiley) is a global research and learning company that publishes over 1,900 peer-reviewed scientific, technical, medical, and scholarly journals along with academic and professional books, encyclopedias, and digital content .
- 🎯 Current $52.49 is 6% below 3yr high $55.72 · ⏳ SMA200 $38.02 (current price $52.49 is above) · 💰 Market Cap $2.8B
- WLY presents a compelling setup with strong technicals and positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (8.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 103% (>20%); ROE 26% (>15%); Low LT D/E 0.81 (<1.0).
⏰ Entry (E): 9/20
- 🔔 Strong above EMA50 (10.4%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (58) — BEARISH
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ John Wiley & Sons (NYSE:WLY) Sets New 52-Week High — MarketBeat.
🤖 The stock reaching a new 52-week high suggests strong recent market momentum for WLY. The article also notes a dividend increase and a recent upgrade from Weiss Ratings, both supportive signals for the share price.
✅ John Wiley & Sons A stock hits 52-week high at 53.0 USD — Investing.com.
🤖 This piece highlights WLY's new 52-week high and strong year-to-date gains, which are bullish for the stock. It also references the company’s recent earnings beat on adjusted EPS and a higher dividend, reinforcing positive investor sentiment.
⚪️ John Wiley & Sons, Inc. $WLY Stake Lessened by Clarkston Capital Partners LLC — MarketBeat.
🤖 This is a routine ownership filing and does not indicate a direct operational change at the company. It mentions the recent earnings beat and dividend increase, but the article itself is mainly about a stake reduction rather than a fundamental development.
⚪️ Hillsdale Investment Management Inc. Increases Stake in John Wiley & Sons, Inc. (WLY) — MarketBeat.
🤖 This is another ownership-change filing rather than a company operating update. It references the recent earnings beat and dividend increase, but the primary news is simply that an investor increased its stake.
🍭 Bonus (B): 0/10 — Book Publishing

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $55.97 is 2% below 3yr high $57.10 · ⏳ SMA200 $45.50 (current price $55.97 is above) · 💰 Market Cap $14.2B
- EXEL passed all filters and shows favorable conditions.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (9.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 44% (>20%); ROE 43% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 5/10
- 🗞️ News sentiment is neutral.
⚪️ Exelixis to Release Second Quarter 2026 Financial Results — Yahoo Finance.
🤖 This is a routine earnings-date announcement that only says when Exelixis will report results and host a call. It does not contain financial results, guidance, or analyst opinion, so it is not material stock news.
⚪️ Exelixis (EXEL) Projected to Release Quarterly Earnings on Wednesday, 2026-07-29 — MarketBeat.
🤖 This is another pre-earnings notice focused on the expected report date and consensus figures. Because it is just a scheduling item rather than new business information, it has limited direct impact on the stock.
⚪️ Exelixis Q2 2026 Earnings Report — MarketBeat.
🤖 This appears to be an earnings-results page tied to Exelixis's second-quarter report, but the snippet provided does not show the actual reported numbers. Without the underlying results or management commentary, the stock impact cannot be assessed from the search result alone.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Vericel Corporation is a biopharmaceutical company that develops, manufactures, and markets advanced cell therapies and specialty biologics for sports medicine and severe burn care. Its main products include MACI for knee cartilage repair, Epicel for severe burns, and NexoBrid for eschar removal in burn treatment.
- 🎯 Current $47.61 is 23% below 3yr high $61.80 · ⏳ SMA200 $37.24 (current price $47.61 is above) · 💰 Market Cap $2.4B
- VCEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 500% (>20%); Revenue growth 22% (>15%); Low LT D/E 0.04 (<1.0); PEG ratio 0.20 (<1.5).
⏰ Entry (E): 3/20
- 🔔 Strong above EMA50 (12.2%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Vericel Q2 2026 Earnings Call Highlights — Yahoo Finance.
🤖 Vericel reported record second-quarter revenue of $77.5 million, positive GAAP net income, and strong free cash flow, while also raising full-year revenue guidance. The article is bullish for VCEL because it highlights accelerating growth, improved profitability, and higher management outlook.
✅ Vericel Reports Second Quarter 2026 Financial Results, Net Income of $2.2 Million and Free Cash Flow of $14.3 Million, Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million, Board of Directors Authorizes $200 Million Share Repurchase Program — GlobeNewswire.
🤖 The company posted 22% revenue growth, turned profitable in Q2, raised full-year revenue guidance, and authorized a $200 million buyback. These are all stock-supportive developments that signal stronger operations and capital returns.
✅ Vericel Q2 2026 slides: record revenue, first profitable quarter — Investing.com.
🤖 This report emphasizes Vericel’s record quarterly revenue, first profitable second quarter, and strong cash generation, with the stock trading higher after the announcement. It is positive for VCEL because it frames the quarter as a meaningful profitability inflection point.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: American Healthcare REIT, Inc. (NYSE: AHR) is a real estate investment trust that acquires, owns, and operates a diversified portfolio of clinical healthcare properties, focusing primarily on senior housing communities, skilled nursing facilities, and outpatient medical buildings across the United States, the United Kingdom, and the Isle of Man.
- 🎯 Current $55.73 is 3% below 3yr high $57.72 · ⏳ SMA200 $49.21 (current price $55.73 is above) · 💰 Market Cap $10.6B
- AHR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 55/60
- 🏦 Low drawdown (14.1% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 425% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 55 in healthy mid-range
- ⚠️ RSI reversing from overbought (55) — BEARISH
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ American Healthcare REIT (NYSE:AHR) Sets New 52-Week High on Analyst Upgrade — MarketBeat.
🤖 Citizens JMP raised its price target on AHR from $60 to $65 and kept an outperform rating, which is typically bullish for the stock. The article also notes that the shares hit a new 52-week high, reinforcing the positive price reaction.
✅ American Healthcare REIT (AHR) Announces ... — Yahoo Finance.
🤖 The article highlights Barclays initiating coverage of AHR and notes the company’s public offering and recent Russell index changes. New coverage from a major bank can broaden investor awareness, while the equity raise and index reclassification may affect trading dynamics.
⚪️ American Healthcare REIT Announces Dates for Second Quarter 2026 Earnings Release and Conference Call — Business Wire.
🤖 This is a bare earnings-date announcement that only gives the release and call schedule, with no results, guidance, or analyst commentary. It is not meaningful stock-specific news by itself and is neutral.
⚪️ American Healthcare REIT reported mixed quarterly results, with EPS of $0.13 coming in below expectations while revenue rose 20.4% year over year to $650.77 million. — MarketBeat.
🤖 The article describes mixed earnings: revenue growth was strong, but EPS missed estimates. Because the headline news is a balance of positives and negatives, the overall stock impact is neutral.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: CSX Corporation is a holding company primarily operating CSX Transportation, a Class I freight railroad with over 21,000 miles of track in the eastern United States and parts of Canada. It transports commodities and manufactured goods, including merchandise freight (e.g., chemicals, metals, automotive), bulk freight, intermodal containers, and provides vehicle shipping services.
- 🎯 Current $50.19 is 6% below 3yr high $53.23 · ⏳ SMA200 $41.06 (current price $50.19 is above) · 💰 Market Cap $93.4B
- CSX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 Low drawdown (11.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 23% (>20%); ROE 38% (>15%); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 53 in healthy mid-range
- ⚠️ RSI reversing from overbought (53) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ CSX (CSX) Q2 Earnings and Revenues Top Estimates — Yahoo Finance.
🤖 CSX reported quarterly EPS of $0.54 and revenue of $3.94 billion, both above consensus estimates. Beating expectations is typically supportive for the stock, especially alongside the reported year-over-year growth in earnings and sales.
✅ CSX Q2 2026 slides: record revenue, margin expansion top estimates — Investing.com.
🤖 This article says CSX’s second-quarter results exceeded Wall Street expectations and that shares rose in after-hours trading. The report highlights record revenue and margin expansion, which are constructive signals for the stock.
✅ Are Wall Street Analysts Bullish on CSX Corporation Stock? — Yahoo Finance.
🤖 The article reports that Deutsche Bank maintained a Buy rating and raised its price target to $59 after CSX’s strong Q2 results. Higher target prices and bullish analyst commentary are generally positive catalysts for the stock.
🍭 Bonus (B): 0/10 — Railroads